(NASDAQ:SLNO),
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”), have until May 5, 2026 to seek appointment as lead plaintiff of the Soleno class action lawsuit. Captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979 (N.D. Cal.), the Soleno class action lawsuit charges Soleno and certain of Soleno's top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Soleno class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-soleno-therapeutics-inc-class-action-lawsuit-slno.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: Soleno is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases. At the time of the Soleno class action lawsuit's filing, Soleno's only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome (“PWS”).
The Soleno class action lawsuit alleges defendants throughout the Class Period failed to disclose that: (i) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.
On August 15, 2025, the Soleno investor class action alleges that Scorpion Capital LLC published a critical report regarding Soleno, DCCR, and Soleno's Phase 3 clinical trial program, titled “Russian Roulette With Prader-Willi Children: How The Latest Rare Disease Price-Gouging Scheme Fleeced the FDA, Parents, And Its Own Study Investigators With A Worthless, Toxic Drug; Suspect Data; And Sham Clinical Trials To Push A $500K/Year Knockoff Of A 50-Year-Old Generic Compound – Triggering One Of The Worst Launch Failures And Safety Catastrophes In Post-Approval History.” On this news, the price of Soleno common stock declined nearly 12% over two trading days, the complaint alleges.
Then, on September 10, 2025, Soleno filed with the U.S. Securities and Exchange Commission a current event report on Form 8-K disclosing that a patient had died after taking DCCR, the Soleno shareholder lawsuit alleges. On this news, the price of Soleno common stock declined approximately 19% over two trading days, the complaint alleges.
Finally, on November 4, 2025, Soleno reported its financial results for its third fiscal quarter ended September 30, 2025, revealing that the Scorpion Capital Report had caused a “disruption” in DCCR's launch trajectory and concerns within the PWS community, with a lower number of patient start forms and increased discontinuations beginning after the report's publication, the Soleno class action alleges. On this news, the price of Soleno common stock declined approximately 27%, the complaint alleges
The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Soleno common stock during the Class Period to seek appointment as lead plaintiff in the Soleno class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Soleno investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Soleno shareholder class action lawsuit. An investor's ability to share in any potential future recovery of the Soleno class action lawsuit is not dependent upon serving as lead plaintiff.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com
